Supernus Pharmaceuticals, Inc. · GETTEX:S49

Supernus Pharmaceuticals, Inc. financial statements

Supernus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue1.24B1.19B1.09B901.0M
Cost of revenue246.0M231.0M174.0M151.0M
Gross profit994.0M957.0M919.0M749.0M
Research and development97.0M107.0M116.0M74.0M
Selling, general and administrative634.0M612.0M565.0M466.0M
Operating income262.0M38.0M-152.0M-77.0M
Depreciation and amortization10.0M16.0M15.0M16.0M
EBITDA272.0M54.0M-137.0M-61.0M
Interest expense45.0M41.0M35.0M27.0M
Income before tax239.0M20.0M-145.0M-86.0M
Income tax29.0M13.0M-19.0M-43.0M
Net income210.0M7.00M-126.0M-42.0M
Earnings per share, basic1.680.05-0.92-0.30
Earnings per share, diluted1.640.05-0.92-0.30

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents195.0M319.0M316.0M774.0M
Short-term investments01.00M94.0M
Receivables253.0M254.0M254.0M
Inventory153.0M167.0M126.0M
Current assets652.0M827.0M1.26B
Property, plant and equipment144.0M100.0M84.0M
Goodwill2.00M2.00M5.00M
Total assets1.20B1.32B1.76B
Accounts payable48.0M63.0M39.0M
Current liabilities914.0M924.0M1.28B
Long-term debt290.0M315.0M237.0M
Total debt319.0M333.0M240.0M
Total liabilities1.30B1.65B1.94B
Shareholders' equity-98.0M-337.0M-184.0M-15.0M
Shares outstanding118.0M118.0M125.1M125.1M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-27.0M36.0M-300.0M-4.00M
Capital spending-66.0M-29.0M-8.00M-5.00M
Free cash flow-93.0M7.00M-308.0M-9.00M
Cash from investing-66.0M69.0M-95.0M-222.0M
Cash from financing-30.0M-102.0M-64.0M-101.0M
Share buybacks-11.0M-173.0M-33.0M-90.0M
Change in cash-124.0M3.00M-459.0M-327.0M